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Heart failure contributes to more than 1 million hospitalizations annually and
is one of the most common causes of repeat hospitalizations in the elderly.
Previously, it was thought that mortality from heart failure with preserved
ejection fraction (PEF) was lower than that from heart failure with reduced
ejection fraction (REF), but more recent data infer similar mortality.
Although the mortality rate in patients with heart failure with REF is
decreasing, the mortality rate in patients with heart failure with PEF remains
unchanged—possibly due to the lack of evidence-based treatment regimens or
greater recognition of the disease. Without sufficient trials in patients with
heart failure with PEF, clinicians are forced to extrapolate treatment from data
proven to benefit patients with heart failure with REF. There is no question
that clinical trials including only patients with heart failure with PEF are
limited. In addition, the definition and clinical diagnosis of this syndrome are
not clearly defined, and the guidelines available for treatment lack specificity
in recommendations. To describe the current literature for the treatment of
heart failure with PEF, we conducted a MEDLINE search of the English-
language literature (1950–2009) to identify studies that pertain to the
treatment of patients with heart failure with PEF. Ongoing clinical trials
continue, but until data become available, clinicians must base their treatment
strategies for heart failure with PEF on sparse information.
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Diastolic dysfunction is defined as increased
resistance to the filling of one or both ventricles
due to decreased ventricular relaxation and/or
increased ventricular stiffness. Diastolic
dysfunction may or may not result in the clinical
syndrome of diastolic heart failure, which occurs
with maintenance of normal left ventricular
ejection fraction (LVEF).1, 2 Diastolic heart
failure is also termed heart failure with preserved
ejection fraction (PEF), heart failure with normal
ejection fraction, and heart failure with preserved
systolic function. For the remainder of this
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review, systolic heart failure or heart failure with
reduced ejection fraction will be referred to as
heart failure with REF, and diastolic heart failure
will be referred to as heart failure with PEF.
In this review, our aim was to identify and
summarize key trials and strategies for the
treatment of patients with heart failure with PEF.
Therefore, we conducted a MEDLINE search of
the English-language literature (1950–2009) to
identify studies that pertain to the treatment of
patients with heart failure with PEF; additional
citations were obtained from the articles retrieved
from the literature search.
Epidemiology and Outcomes
The 2010 estimated direct and indirect cost of
heart failure in the United States was $39.2
billion.3 Heart failure contributes to more than 1
million hospitalizations annually and is one of
the most common causes of repeat hospitalizations
in the elderly.4 The prevalence of heart failure
with PEF in the community is estimated to be
43–71% of patients with heart failure.5 In a 15-
year study of 4596 patients with acutely decom-
pensated heart failure who were discharged with
echocardiographic assessment, 53% had reduced
LVEF (< 50%) and 47% had preserved LVEF (≥
50%).6 Over three consecutive 5-year increments,
the proportion of admissions for heart failure
with PEF increased from 38% to 47% to 54%.
Patients with heart failure with PEF have a
substantial risk of death, although the reported
rates varied due to patient selection criteria and
the population studied (Table 1).6–13 A cumu-
lative review of heart failure–related mortality
published in 2009 concluded that all-cause
mortality was equivalent in patients who had
heart failure with PEF and those who had heart
failure with REF, both in the community setting
and in those hospitalized with acutely decom-
pensated heart failure.5 Over time, the mortality
rate in patients with heart failure with REF have
decreased, whereas the mortality rate in those
with heart failure with PEF has remained
unchanged. Compared with patients with heart
failure with REF, more deaths in patients with
heart failure with PEF are noncardiac, a
distinction that may have important implications
for clinical trial design.14
Clinical Presentation and Diagnosis
The manifestation of heart failure with PEF is
similar to that of heart failure with REF, and
typically patients report fluid retention, dyspnea,
fatigue, and exercise intolerance. The hetero-
geneity of the heart failure with PEF patient
population makes defining diagnostic criteria and
understanding pathophysiology a difficult task.
Controversy exists as to whether or not heart
failure with PEF can be diagnosed simply in the
presence of preserved LVEF and symptoms of
heart failure, or whether objective measurements
of ventricular diastolic function are needed to
confirm the diagnosis.15 Transthoracic echocardio-
graphy is widely available and noninvasive, and
is the most commonly used modality to assess
diastolic function. Classic parameters include
assessment of mitral inflow velocities (i.e., the
ratio between early [E] velocity from ventricular
filling to late velocity from atrial contraction [A],
the E:A ratio), pulmonary vein velocities, and
isovolumic ventricular relaxation time. More
recent variables include tissue Doppler velocity
measurements at the mitral annulus, color M-
mode propagation velocity, and diastolic ventricu-
lar strain rates (rate or speed of myocardial
shortening or thickening used to assess diastolic
stiffness). All of these measures have limitations
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Table 1. Mortality in Patients with Heart Failure: PEF versus REF
Patients with PEF Heart Failure Patients with REF Heart Failure
LVEF Mortality LVEF Mortality
Patient Population (%) (%) (%) (%)
Community7 ≥ 50 8.7 < 50 18.9
Hospitalized8 > 55 23.5 < 55 16–51.7
Hospitalized9 > 48 19 < 36 > 25
Community10 ≥ 50 16 < 50 16
Hospitalized11 ≥ 40 21 < 40 13
Hospitalized6 ≥ 50 65 < 50 68
Hospitalized12 > 50 22 < 40 26
Hospitalized13 > 55 3a < 55 3.2–4.7a
PEF = preserved ejection fraction; REF = reduced ejection fraction; LVEF = left ventricular ejection fraction.
aIn-hospital mortality reported.
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related to acquisition of data, dependence on
loading conditions, and/or reproducibility; the
guidelines for echocardiographic assessment of
diastolic function are frequently changing.16
The Heart Failure and Echocardiography
Association of the European Society of Cardiology
defines the following three criteria for the
diagnosis of heart failure with PEF: signs or
symptoms of heart failure; normal or mildly
abnormal systolic left ventricular function,
defined as an LVEF greater than 50% without
severe dilation of the left ventricle; and evidence
of diastolic left ventricular dysfunction, defined
invasively by elevated filling pressures at left-
sided heart catheterization or noninvasively by
echocardiography.17 The Heart Failure Society of
America (HFSA) states that the diagnosis of heart
failure with PEF can be made by the combination
of clinical symptoms and preserved or relatively
preserved LVEF.18 In the American College of
Cardiology–American Heart Association (ACC-
AHA) 2005 heart failure guidelines, definitive
diagnosis is based on symptomatic presentation
and evidence of normal LVEF without valvular
abnormalities at echocardiography.19 The 2009
ACC-AHA heart failure guidelines make no new
mention of using cardiac catheterization as a
preferred method of diagnosis,20 as is suggested
by others.21 Overall, symptomatic presentation
and preserved LVEF will continue to be used as
the guideline-based diagnostic criteria for heart
failure with PEF, but catheterization may be
helpful in cases where the diagnosis is unclear.22
Increased natriuretic peptides (B-type [brain]
natriuretic peptide [BNP] and N-terminal
proBNP [NT-proBNP]) may also have a role in
detecting patients with diastolic dysfunction
and/or heart failure with PEF. A subset of
patients from the Candesartan in Heart Failure
Assessment of Reduction in Mortality and
Morbidity (CHARM) trial with preserved LVEF
(181 patients) was classified as having mild,
moderate, or severe diastolic dysfunction.23 A
BNP level greater than 100 pg/ml or an NT-
proBNP level greater than 600 pg/ml was the
strongest predictor of moderate or severe
diastolic dysfunction. In addition, an elevated
BNP level was the most accurate predictor of
severe diastolic dysfunction in a direct comparison
of 294 patients with either normal or abnormal
diastolic function.24 The European Society of
Cardiology guidelines take these findings into
account, as a BNP level greater than 200 pg/ml or
NT-proBNP level greater than 220 pg/ml may be
used to diagnose heart failure with PEF in the
setting of indeterminate diastolic function by
echocardiography.17 However, low natriuretic
peptide levels cannot be used to rule out a
diagnosis of heart failure with PEF,25 and high
levels do not necessarily mean that an individual
patient has heart failure with PEF, a clinical
diagnosis based on signs and symptoms.
Pathophysiology
Because of increased ventricular stiffness and
impaired ventricular relaxation, many patients
with heart failure with PEF have an inability to
increase left ventricular end-diastolic volumes
and use the Frank-Starling mechanism to
increase cardiac output.26 Cellular mechanisms
of diastolic dysfunction include abnormalities of
calcium homeostasis changes in cardiomyocytes,
cytoskeletal proteins and their phosphorylation
status, and the regulatory processes of collagen
formation and degradation. However, the initial
focus on intrinsic ventricular diastolic dysfunc-
tion26, 27 as the primary cause of heart failure with
PEF has broadened to include other extrinsic
contributing factors including arterial stiffening,28
endothelial dysfunction,29, 30 chronically increased
plasma volume,31 impaired atrial transport
function,32 chronotropic incompetence (inadequate
heart rate response to exercise),29 pulmonary
hypertension,33 and even subtle ventricular
systolic dysfunction.34
The renin-angiotensin-aldosterone system
(RAAS) is associated with many of the contributing
causes of heart failure with PEF and is therefore
thought to be associated with disease progression
(Table 2).35, 36 Chronically overactive sympathetic
nervous system activity may contribute to both
types of heart failure (PEF and REF), as
norepinephrine levels are markedly higher in
both patients with PEF and those with REF than
norepinephrine levels in control subjects.37
Patients with heart failure with PEF have reduced
responsiveness to -adrenergic stimulation due to
reduced numbers of adrenergic receptors and
reduced signaling, which may contribute to
chronotropic incompetence compared with healthy
and hypertensive control subjects.38 Results of a
recent analysis of the Health, Aging, and Body
Composition (Health ABC) study, a large cohort
of community-dwelling and previously healthy
elderly subjects, suggest that chronic inflam-
mation may play a key role in the genesis and
progression of heart failure with PEF.39
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Risk Factors and Prevention
Risk factors for heart failure with PEF include
increasing age, hypertension, and coronary artery
disease,40 although coronary artery disease is less
prevalent than in heart failure with REF.13, 41
Patients with heart failure with PEF are predomi-
nantly female,12, 13, 41–48 with a sex association
remaining after adjustment for other predictors.49
Greater frequencies of hypertension, atrial
fibrillation, valvular heart disease, and chronic
obstructive pulmonary disease have also been
seen with heart failure with PEF versus heart
failure with REF.12, 48 Diabetes mellitus is an
independent predictor of mortality50, 51 in patients
with heart failure with PEF and is associated with
a significantly greater risk of death or heart
failure hospitalization.51 Factors that precipitate
heart failure exacerbation and fluid retention in
patients with heart failure with PEF are similar to
those of heart failure with REF and include
increasing age, uncontrolled hypertension, atrial
fibrillation, drug therapy noncompliance,
ischemia, anemia, renal insufficiency, and dietary
noncompliance.15
Treatment
The ACC-AHA, European Society of Cardiology,
and HFSA treatment guidelines for heart failure
with PEF focus on the control of physiologic
factors known to adversely affect ventricular
diastolic function, including blood pressure,
heart rate, blood volume, and myocardial ischemia.
However, most of the recommendations are based
on expert consensus, and the ACC-AHA
guidelines highlight the need for more controlled
clinical trials in patients with heart failure with
PEF. For the purposes of this review, only
published treatment studies that specifically
enrolled patients with heart failure with PEF are
discussed.
Angiotensin-Converting Enzyme Inhibitors and
Angiotensin II Receptor Blockers
The benefits of angiotensin-converting enzyme
(ACE) inhibitors and angiotensin II receptor
blockers (ARBs) in patients with heart failure
with REF are well described, but there are several
specific reasons why these agents could be
advantageous in those with heart failure with
PEF as well. Angiotensin II promotes interstitial
collagen deposition and fibrosis, causing
myocardial thickening and decreased ventricular
compliance21; it may impair ventricular relaxation.
Moreover, angiotensin II increases systemic
vascular resistance and vascular stiffness, which
contribute to hypertension and increased
ventricular afterload.
An early study compared the effects of
enalapril versus placebo in 22 patients with heart
failure, normal LVEF (> 50%), and ability to
complete a maximal exercise test.52 Diagnostic
criteria for heart failure included presence of
rales heard by two cardiologists and pulmonary
vascular congestion on chest radiograph. All
patients received more than 2 weeks of
furosemide before the study and continued on a
stable dose throughout the study. Digoxin and
other cardiac drugs were prohibited. Patients in
the enalapril arm began therapy by taking 2.5
mg/day, which was increased over 5 weeks to a
maximum of 10 mg twice/day. After 3 months,
the enalapril group showed a benefit in New York
Heart Association (NYHA) functional class,
reduction in cardiothoracic ratio, increase in
treadmill exercise duration, improvement in left
ventricular systolic and diastolic function, and
reduction in left ventricular mass, all of which
were statistically significantly different from
those changes in the placebo group. Although
echocardiographic parameters were blinded, a
major limitation of this study was the nonblinded
assessment of both functional capacity and
treadmill exercise duration.
A randomized, double-blind, placebo-controlled
crossover study of losartan versus placebo tested
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Table 2. Pathophysiologic Characteristics of Patients with
Heart Failure: PEF versus REF
Parameter PEF REF
LVEF Normal Decreased
LVEDP Increased Increased
PCWP Increased Increased
Cardiac output Normal or Decreased
decreaseda
Stroke volume Normal or Decreased
decreaseda
Diastolic function Impaired Normal or
impaired
BNP Normal or Increased
increased
Neurohormonal Increased Increased
activation
Left ventricular Increased Decreased
wall thickness
PEF = preserved ejection fraction; REF = reduced ejection fraction;
LVEF = left ventricular ejection fraction; LVEDP = left ventricular
end-diastolic pressure; PCWP = pulmonary capillary wedge
pressure; BNP = B-type (brain) natriuretic peptide.
aCardiac output and stroke volume may be normal at rest and
abnormal with exercise.
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the hypothesis that angiotensin II blockade
would improve exercise tolerance in patients
with diastolic dysfunction.42 Patients included
were asymptomatic at rest, but had dyspnea with
exertion and were undergoing exercise testing for
evaluation of coronary artery disease. Patients
previously taking ARBs and with concurrent
exercise-limiting disease were excluded. All
patients’ baseline drug therapies were continued
throughout the study (35% were taking -
blockers, 30% diuretics, 25% calcium channel
blockers, and 30% ACE inhibitors). The mean
baseline systolic blood pressure at rest and
during exercise was 143 ± 8 and 226 ± 24 mm
Hg, respectively, and the mean baseline exercise
time was 11.3 ± 2.5 minutes. Patients completed
a baseline Minnesota Living with Heart Failure
Questionnaire, treadmill exercise tests using the
modified Bruce Protocol with blood pressure
measurements, and Doppler echocardiography
after exercise; all of which were repeated at the
end of each phase. Patients assigned to the
losartan treatment showed significantly decreased
peak systolic blood pressure during exercise,
increased exercise tolerance, and improved
quality of life (all compared with baseline values)
in this 2-week crossover study. Resting blood
pressure and echocardiographic measures of
diastolic function were not significantly different
from baseline. Limitations to this study included
the presence of other baseline drugs that reduced
the ability to see the effects of losartan alone, as
well as the short treatment time. The authors
suggested that since ACE inhibitors do not
prevent increased angiotensin II during exercise,
they also may not be able to produce the same
reduction in exercise-mediated increased systolic
blood pressure as demonstrated with losartan.
A double-blind, placebo-controlled study
compared the effects of quinapril versus placebo
in 74 symptomatic patients with heart failure
with PEF.53 Quinapril was started at 5 mg/day
and increased to 40 mg/day within 6 weeks.
Treatment with diuretics (> 90% of patients),
nitrates, digoxin (> 25%), calcium channel
blockers (> 15%), and -blockers (> 7%) was
continued, but ACE inhibitors were withdrawn 2
weeks before the run-in period. Mean 6-minute
walk distances increased at 6 months and
quality-of-life scores increased from baseline, but
not significantly for either end point. Compared
with the placebo group, patients receiving
quinapril tended to be less likely to experience
worsened heart failure (15.8% vs 11.1%,
p=0.737) or hospital admission due to heart
failure (13.1% vs 5.6%, p=0.431).
The Perindopril in Elderly People with
Chronic Heart Failure (PEP-CHF) trial randomly
assigned 850 patients in a double-blind fashion
to receive perindopril or placebo.44 All patients
were older than 70 years, treated with diuretics,
had a clinical diagnosis of heart failure (meeting
at least two of four echocardiographic criteria),
were able to walk without assistance of another
person, and had to have a heart failure hospital-
ization within the past 6 months. Excluded
patients had a wall motion abnormality equivalent
to LVEF less than 40%, hemodynamically
significant valvular disease, stroke within the
previous month, systolic arterial pressure less
than 100 mm Hg, serum creatinine level greater
than 2.3 mg/dl, potassium level greater than 5.4
mEq/L, history of ACE inhibitor intolerance, use
of ACE inhibitor or ARB within the previous
week, or use of potassium or potassium-sparing
diuretics (other than low-dose spironolactone).
The primary end point was a composite of all-
cause mortality and unplanned heart failure–
related hospitalization, and the mean follow-up
was 26.2 months. Many patients were also
receiving -blockers (~55%), loop diuretics
(~45%), and calcium channel blockers (~33%),
and approximately 50% were receiving nitrates
and digoxin. Patients assigned to receive
perindopril began by taking 2 mg/day with
titration to 4 mg/day (~90% titrated).
Unfortunately, with lower than anticipated
enrollment, a lower than expected event rate, and
increased use of open-label ACE inhibitor,
recruitment was stopped early, and only 107 and
100 patients receiving perindopril and placebo,
respectively, reached the primary end point
(p=0.545). Looking at only the first year of data,
65 patients (15.3%) in the placebo group and 46
patients (10.8%) in the perindopril group
reached the primary outcome (p=0.055), but this
study was underpowered for its primary end
point with only a calculated 35% power to show
statistical significance. During the first year,
12.4% of the placebo group and 8.0% of the
perindopril group had an unplanned hospital-
ization for heart failure (p=0.033), but this was
not significant over the entire study period. Of
hospitalized patients, those in the perindopril
group spent a median of 3 fewer days admitted
for cardiovascular reasons (p=0.056) and 5 fewer
days for any reason (p=0.229). Of note,
perindopril treatment produced significant
improvement in NYHA classification and 6-
minute walk distance. A major limitation of this
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study was its lack of power for primary
outcomes. In addition, authors noted that the
clinical diagnosis of heart failure was only
partially corroborated by patient characteristics.
One important observation in this trial was the 3-
fold increase in primary end point in patients
with NT-proBNP levels above the median value;
the authors suggested this may be a key selection
criterion for future clinical trials. One of the
strengths of this study was its exclusion of
patients taking ACE inhibitors or ARBs.
The CHARM-Preserved study compared
candesartan versus placebo in patients with heart
failure with PEF; the primary outcome was
cardiovascular death or hospital admission for
worsening heart failure.54 Patients were permitted
concomitant use of other drugs: -blockers
(~55% of patients), diuretics (~75%), calcium
channel blockers (~31%), ACE inhibitors
(~19%), digoxin (~28%), and spironolactone
(~12%). Patients were randomly assigned in a
double-blind fashion to placebo or candesartan
with initial doses of 4 or 8 mg/day, with dose
doubling every 2 weeks to a target dose of 32 mg.
Of note, patients in the candesartan group had
higher prevalence of several baseline characteristics
associated with poorer prognosis, including
previous myocardial infarction, stroke, current
smoking, hypertension, diabetes, and cancer.
After a median of 36.6 months’ follow-up,
significantly fewer patients in the candesartan
group had at least one hospitalization for heart
failure (230 vs 279 patients, p=0.017). Candesartan
did not reduce the frequency of the primary end
point (22% for candesartan vs 24% for placebo,
p=0.118), although when adjusted for other
predictors the difference approached statistical
significance (p=0.051). Approximately 19% of
patients were concurrently receiving ACE
inhibitors, which may have limited the ability to
target candesartan’s benefit on RAAS blockade.
The Irbesartan in Patients with Heart Failure
and Preserved Ejection Fraction (I-PRESERVE)
trial included 4128 patients aged 60 years or
older with heart failure symptoms and LVEF
greater than 45% who were either hospitalized in
the last 6 months for heart failure with current
NYHA classes II–IV symptoms or persistent
NYHA classes III–IV symptoms.43 Patients with
ACE inhibitor intolerance, probable alternative
cause of symptoms, previous LVEF less than
40%, history of acute coronary syndrome,
coronary revascularization or stroke within 3
months, valvular abnormalities, hypertrophic or
restrictive cardiomyopathy, pericardial disease,
cor pulmonale or other right-sided heart failure,
systolic blood pressure less than 100 or greater
than 160 mm Hg or diastolic blood pressure
greater than 95 mm Hg despite antihypertensive
therapy, life expectancy less than 3 years (due to
other systemic disease), hemoglobin level less
than 11 g/dl, serum creatinine concentration
greater than 2.5 mg/dl, liver function abnor-
malities, or characteristics that would inhibit
compliance were excluded. The primary
outcome was a composite of death from any
cause or hospitalization for a cardiovascular
cause. Secondary outcomes included a break-
down of components from the primary outcome,
as well as proBNP levels and the Minnesota
Living with Heart Failure Scale. Baseline drug
therapy included diuretics (83% of patients), -
blockers (59%), calcium channel blockers (40%),
spironolactone (15%), and ACE inhibitors (25%).
Patients successfully completing a 1–2 week run-
in phase were randomly assigned to receive
irbesartan or placebo stratified by baseline ACE
inhibitor use. In patients assigned to receive
irbesartan, the dosage began with 75 mg once/day
and increased to 300 mg/day (target dose) as
tolerated.
Patients in I-PRESERVE were more similar to
patients participating in epidemiologic heart
failure with PEF studies than those in previous
trials, including the breakdown by sex, with
more female than male patients. Although ACE
inhibitor use was intended to be capped at 33%
of the population and only permitted if essential
for an indication other than hypertension, the
proportion of patients receiving an ACE inhibitor
was 39% and 40% in the irbesartan and placebo
groups, respectively. No significant benefit was
seen in primary or secondary outcomes. Patients
in the irbesartan and placebo groups had a
respective 36% and 37% rate of composite death
from any cause or hospitalization for a cardio-
vascular cause (p=0.35). The authors noted
several possibilities that could have led to the
negative trial results, including a high rate of
study drug discontinuation (~34% total;
discontinuation due to an adverse event 16% for
irbesartan vs 14% for placebo, p=0.07); frequent
use of other drugs affecting the RAAS system,
including approximately 40% ACE inhibitors,
73% -blockers, and 30% spironolactone; and a
potentially suboptimal irbesartan dose.
Despite the largely disappointing results of
heart failure with PEF treatment trials, many
believe that ACE inhibitors and ARBs have the
potential to prevent development of heart failure
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with PEF. However, few studies focusing on
prevention have been published, and results have
not clearly shown benefit. As part of the
Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT),
lisinopril was compared with chlorthalidone in
patients with hypertension.41 Chlorthalidone was
found to decrease the frequency of new-onset
heart failure significantly more than lisinopril
(see Diuretic section for details). In the Valsartan
in Diastolic Dysfunction (VALIDD) study,
authors hypothesized that ARBs would improve
ventricular diastolic function in patients with
hypertension before the development of heart
failure with PEF.55 Patients were randomly
assigned to receive valsartan 160 mg once/day
titrated to a goal of 320 mg/day or a non–RAAS-
blockade regimen with instructions to control
systolic blood pressure to less than 135 mm Hg
in both groups. Although valsartan treatment did
indeed improve ventricular diastolic function,
equal blood pressure control with a non-ARB
regimen improved diastolic function to a similar
degree.
To summarize, several small studies with ACE
inhibitors and ARBs showed symptomatic
improvement, increased exercise capacity, increased
quality of life, and reduced left ventricular mass
(Table 3).41–47, 52–54, 56–64 The CHARM-Preserved
trial suggested a benefit in reducing hospital
admissions for heart failure,54 but this result was
not confirmed in the more contemporary I-
PRESERVE trial.43 These inconsistent results
between two of the largest available trials in heart
failure with PEF may be related to concurrent
ACE inhibitor use, which made up approxi-
mately 20% compared with 40% of enrolled
patients in the CHARM-Preserved and I-
PRESERVE trials, respectively. Other important
differences between these trial populations
include age (67 vs 72 yrs), sex (~40% vs 60%
female), and LVEF (mean ~54% vs 60%).
The 2008 European Heart Failure guidelines
suggest that ACE inhibitors and ARBs be first-
line therapy for hypertension control in patients
with heart failure with PEF.65 The HFSA
recommends that blood pressure be controlled
(target < 130/80 mm Hg) and consideration given
to treatment with an ACE inhibitor or ARB.
These guidelines also recommend the consider-
ation of an ACE inhibitor in all patients with
atherosclerotic heart disease or diabetes with one
additional risk factor (ARBs should be considered
if intolerant to ACE inhibitors).18 With
hypertension as a common cause of heart failure
with PEF, it is reasonable to use an ACE inhibitor
or ARB for blood pressure reduction, athero-
sclerotic heart disease, or diabetes, but there is a
lack of information to support use of these agents
in a patient with controlled hypertension without
another indication.
Aldosterone Antagonists
Aldosterone can promote interstitial collagen
deposition and fibrosis, leading to increased
ventricular stiffness. A prospective, randomized,
double-blind, placebo-controlled trial hypothesized
that spironolactone could prevent cardiac fibrosis
of aging and therefore prevent or delay age-
related worsening of diastolic dysfunction in the
elderly.46 Patients 60–85 years of age with mild
diastolic dysfunction (measured by echocardio-
graphy) were given spironolactone or placebo.
Mitral E:A ratio and deceleration time (load-
dependent echocardiographic measures of
diastolic function), plasma levels of carboxy-
terminal of procollagen type I (PCIP) and BNP
were measured at baseline and after 4 months of
treatment. After 28 patients completed the 4-
month study, the spironolactone group showed
significantly improved E:A ratio and deceleration
time from baseline values versus no significant
changes from baseline in these values in the
placebo group. Although a significant difference
from baseline was noted in the spironolactone
group in both E:A ratio and deceleration time, a
significant difference was not seen with
spironolactone versus placebo at 4 months. No
significant difference in PCIP or BNP levels was
found between groups despite previously
reported decreases in BNP levels with spirono-
lactone treatment in rats with heart failure with
REF.66
Another study randomly assigned 30 carefully
selected patients with hypertensive heart failure
with PEF and confirmed ventricular diastolic
dysfunction to receive spironolactone or placebo.56
Primary end points included changes in long-axis
strain and backscatter parameters (sensitive
echocardiographic measures of ventricular
systolic function) with intervention. Secondary
end points included changes in left ventricular
wall thickness, left ventricular mass, indexes of
diastolic function, and arterial compliance.
Patients included in the study were those with
exertional dyspnea, without ischemia (no history
of angina or myocardial infarction). Patients
were excluded if they were receiving ACE
inhibitor, ARB, or spironolactone therapy, or had
318
TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION Barnes et al 319
Table 3. Published Trials in Patients with Heart Failure with Preserved Ejection Fraction
Study Treatment and
Duration of Follow-up Study Population Study Objective Significant Results
ACE inhibitors and ARBs
Enalapril 2.5–20 mg/day Mean age ~80 yrs, To compare the effects Enalapril vs placebo:
vs placebo x 3 mo52 82% men, of enalapril on elderly ↓ NYHA class: 2.4 ± 0.5 vs 3 ± 0, p=0.005
LVEF > 50%, patients with previous MI ↓ cardiothoracic ratio: 0.52 ± 0.01 vs
NYHA class III, and normal LVEF treated 0.54 ± 0.02, p<0.001
MI > 6 mo prior, with diuretics ↑ treadmill exercise duration: 270 ± 44 vs
mean E:A ratio 0.6 24 ± 27 sec, p<0.001
(n=22) ↑ LVEF: 68 ± 9% vs 64 ± 9%, p<0.05
↑ peak E:A ratio: 0.7 ± 0.1 vs 0.6 ± 0.1,
p<0.001
↓ left ventricular mass: 280 ± 46 vs
313 ± 43 g, p<0.001
Losartan 50 mg/day Mean age 64 yrs, To test the hypothesis Losartan vs placebo:
vs placebo x 2 wks42 80% women, LVEF that ARBs would improve ↓ peak SBP during exercise: 193 ± 27 vs
> 50%, E:A ratio exercise tolerance in 217 ± 26 mm Hg, p<0.05
< 1.0, SBP at rest patients with diastolic ↑ exercise duration: 12.3 ± 2.6 vs
< 150 mm Hg, dysfunction and increase 11.0 ± 2.0 min, p<0.05
SBP with exercise SBP during exercise ↑ quality of life: MLHFQ score 18 ± 22 vs
> 200 mm Hg 22 ± 26, p>0.05
(n=20) ↑ time to SBP > 190 mm Hg during exercise:
10.6 ± 3.3 vs 8.7 ± 3.5 min, p<0.05
Quinapril 5–40 mg/day Mean age ~78 yrs, To evaluate the effect of No significant results reported
vs placebo x 6 mo53 > 30% male, quinapril on functional
LVEF > 40% status of elderly patients
(mean ~59%) with heart failure with
(n=74) PEF and the feasibility
of such studies in elderly
patients
Candesartan 4–32 mg/day Mean age 67 yrs, To assess the effects of Candesartan vs placebo:
vs placebo x 4 wks54 60% men, 64% candesartan on composite ≥ 1 hospital admission for heart failure
had hypertension, outcome of cardiovascular at 36.6 mo of follow-up: 230 vs 279
LVEF > 40% mortality or admission to patients, p=0.017
(mean LVEF 54%) hospital for worsening Total heart failure admissions:
NYHA class II–IV heart failure 402 vs 566 admissions, p=0.014
x 4 wks (> 60%
NYHA class II),
history of hospital
admission (n=3023)
Perindopril 2–4 mg/day Mean age 75 yrs, To determine if perindopril Perindopril vs placebo:
vs placebo x 1 yr44 > 60% NYHA class II, could improve outcomes Patients with NYHA class II: 63.7% vs
mean E:A ratio 0.7, in older patients treated 70.5%, p=0.03
LVEF ≥ 40% for heart failure with ↑ 6-min walk distance: 328 vs 309 meters,
(mean LVEF 64%) evidence of diastolic p=0.011
(n=850) dysfunction
Irbesartan 75–300 mg/day Mean age 72 yrs, To evaluate the effect of No significant results reported
vs placebo x 2 yrs43 60% women, irbesartan on mortality
> 70% NYHA class II, and cardiovascular
LVEF > 45%, 88% morbidity in patients
had hypertension, with heart failure with
mean irbesartan PEF
dose 275 mg
(n=4128)
Aldosterone antagonists
Spironolactone Mean age ~72 yrs, To test the hypothesis that ↑ E:A ratio from baseline: 0.71 ± 0.08 vs
25 mg/day vs 78% female, spironolactone can prevent 0.84 ± 0.19, p=0.025
placebo x 4 mo46 LVEF > 45%, progressive cardiac fibrosis ↓ deceleration time from baseline: 285.5
E:A ratio < 1.0, and prevent or delay ± 73.1 vs 230.0 ± 54.7 msec, p=0.035
> 45% of patients age-related decline in
taking ACE diastolic function in
inhibitor or ARB the elderly
(n=28)
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Table 3. Published Trials in Patients with Heart Failure with Preserved Ejection Fraction (continued)
Study Treatment and
Duration of Follow-up Study Population Study Objective Significant Results
Aldosterone antagonists
(continued)
Spironolactone Mean age > 60 yrs, To determine the effects Spironolactone at baseline vs 6 mo:
25 mg/day vs > 60% female, of spironolactone on ↑ strain rate: −1.57 ± 0.46 vs −1.91 ± 0.36
placebo x 6 mo56 LVEF > 50% myocardial function by sec−1, p<0.01
(mean ~68%), using sensitive quantitative ↑ peak systolic strain: −20.3 ± 5.0% vs
E:A ratio < 1.0 echocardiographic −26.9 ± 4.3%, p<0.001
(n=30) techniques ↓ left ventricular posterior wall thickness:
0.95 ± 15 vs 84 ± 0.14 cm, p=0.04
Eplerenone 25–50 mg/day Mean age 80 yrs, To evaluate the impact of Eplerenone vs placebo:
vs placebo x 12 mo57 64% female, eplerenone on collagen ↓ PIINP from baseline: −0.50 ± 2.01 vs
LVEF > 40%, turnover in patients with 2.13 ± 2.78 g/L, p=0.006
91% had heart failure with PEF ↓ deceleration time from baseline:
hypertension, –82 ± 51 vs −7 ± 73 msec, p= 0.032
64% were taking
ACE inhibitor,
34% ARB, and 68%
-blocker (n=44)
-Blockers
Propranolol 90 mg/day Mean age 81 yrs, To evaluate the effect of Propranolol vs placebo:
vs placebo x 32 mo45 > 70% women, propranolol on total ↑ LVEF: mean 6% vs 2%, p<0.0001
LVEF ≥ 40% mortality and nonfatal MI ↓ left ventricular mass: 34- vs 20-g
(mean ~56%) reduction, p=0.0001
(n=158) ↓ total mortality at 32 mo: 56% vs 76%,
p=0.007
↓ total mortality and nonfatal MI at 32 mo:
59% vs 82%, p=0.002
Atenolol 50–100 mg/day Mean age > 60 yrs, To compare effects of Atenolol vs nebivolol:
vs nebivolol 68% male, atenolol and nebivolol At rest: change from baseline to 6 mo:
2.5–5 mg/day x 6 mo58 LVEF ≥ 50%, on exercise hemodynamic Cardiac index: −0.64 vs −0.26 L/min/m2,
E:A ratio < 1.0 parameters and maximal p=0.01
(n=26) exercise capacity Systemic vascular index: 118 vs 32
dyn•sec/cm5, p=0.05
mPAP: −1 vs −4 mm Hg, p=0.03
PWP: −1 vs −3 mm Hg, p=0.03
↑ E:A ratio: 0.05 vs 0.12, p=0.004
At peak exercise: change from baseline
to 6 mo:
Cardiac index: −0.54 vs −0.05 L/min/m2,
p=0.005)
mPAP: −2 vs −7 mm Hg, p=0.03
PWP: −1 vs −5 mm Hg, p=0.03
Carvedilol 25–50 mg Mean age ~66 yrs, To investigate the effects of Carvedilol vs placebo:
twice/day vs placebo LVEF > 45%, carvedilol in patients with Change from baseline to 6 mo:
x 12 mo59 > 60% had heart failure with PEF ↑ age-adjusted E:A ratio: 0.11 vs 0.05,
hypertension, > 50% p=0.046
NYHA class II,
>10% had diabetes
(n=97)
Carvediolol Mean age 71 yrs, To evaluate the effect of Carvedilol vs conventional therapy:
1.25–20 mg/day vs 48% women, carvedilol vs conventional ↓ BNP: 106 vs 174 pg/ml, p<0.02
conventional LVEF ≥ 45% therapy on NYHA class, ↓ NYHA class: −0.77 vs −0.25, p=0.02
treatment x 12 mo60 (mean 57%) BNP, and exercise capacity ↑ exercise capacity: 5.68 vs 4.72 metabolic
mean E:A ratio 0.74, equivalents, p<0.02
NYHA class II–III,
83% taking ACE
inhibitors, 10%
digitalis (n=40)
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renal impairment, hyperkalemia, or signifi-cant
valvular disease. The spironolactone group
showed a significant reduction in posterior wall
thickness from baseline and a trend toward
reduced left atrial area (p=0.09) and, in addition,
saw a significant increased long-axis strain rate,
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Table 3. Published Trials in Patients with Heart Failure with Preserved Ejection Fraction (continued)
Study Treatment and
Duration of Follow-up Study Population Study Objective Significant Results
-Blockers (continued)
Nebivolol Age ≥ 70 yrs, To examine the effects ↓ heart rate (net effect vs placebo):
1.25–10 mg/day LVEF > 35% of LVEF on outcomes −6.9 beats/min, p<0.001
vs placebo x 21 mo61 (mean 49%) of nebivolol Nebivolol vs placebo:
(n=752; heart ↑ LVEF: 48.7 ± 9.9 at baseline to
failure with PEF) 50.3 ± 11.3 at 12 mo vs 49.1 ± 9.4 at
baseline to 48.4 ± 11.8 at 12 mo, p=0.027
Calcium channel blockers
Verapamil 80 mg Mean age 68 yrs, To evaluate the effects of Verapamil vs placebo:
twice/day to 120 mg 100% men, verapamil in men with Median improvement in heart failure score:
3 times/day vs LVEF > 45% heart failure with PEF 3 vs 1, p<0.01
placebo x 5 wks62 (n=20) ↑ peak filling rate: 2.29 ± 0.54 vs
1.85 ± 0.45 EDV/sec, p<0.05
↑ exercise capacity from baseline:
13.9 ± 4.3 vs 10.7 ± 3.4 min, p<0.05
Verapamil 120 mg/day Age ≥ 60 yrs, To evaluate if verapamil is Verapamil at baseline vs verapamil at 3 mo
vs placebo x 3 mo63 40% female, effective in elderly patients vs placebo at 3 mo:
LVEF > 50%, with left ventricular Improved heart failure score: 5.6 ± 0.5 vs
E:A ratio < 1.0, diastolic dysfunction as 3.5 ± 0.5 vs 5.5 ± 0.5, p<0.05
NYHA class II–III a cause of heart failure ↑ exercise time: 7.4 ± 1.2 vs 8.3 ± 1.2 vs
(n=15) 7.4 ± 1.3 min, p<0.05
↑ Mva:Pva ratio: 0.89 ± 0.08 vs 1.11 ± 0.08
vs 0.91 ± 0.07, p<0.05
↓ isovolumic relaxation time: 84 ± 12 vs
73 ± 9 vs 86 ± 13 msec, p<0.05
Digoxin
Digoxin 0.125–0.5 Heart failure with To examine the effect of ↓ 2-yr heart failure hospitalization:
mg/day vs placebo REF (mean LVEF digoxin on outcomes PEF: HR 0.64, 95% CI 0.45–0.90, p=0.010
x 2 yrs64 ~32%) vs PEF separately in propensity- REF: HR 0.73, 95% CI 0.54–0.97, p=0.033
(mean LVEF 55%) matched patients with ↓ 2-yr heart failure hospitalization or
mean age ~67 yrs, heart failure with REF mortality:
> 30% women, and those with heart PEF: HR 0.69, 95% CI 0.5–0.95, p=0.025
> 50% NHYA class II failure with PEF in REF: HR 0.72, 95% CI 0.55–0.95,
> 25% had diabetes equal samples p=0.0022
> 18% had
hypertension
> 85% taking ACE
inhibitors, > 75%
diuretics, > 65%
mean digoxin dose
0.25 mg (n=1832)
Diuretics
Diuretics vs diuretics Mean age ~74 yrs, To assess the blockade effect ↑ quality-of-life score at baseline vs 1 yr:
+ ramipril 2.5–10 > 30% female, of the renin-angiotensin Diuretics: 20 vs 10.9, p<0.001
mg/day vs diuretics LVEF > 45%, system with an ARB or Diuretics + ramipril: 23 vs 11.4, p<0.001
+ irbesartan 18.75–75 > 80% had ACE inhibitor using Diuretics + irbesartan: 19 vs 9.4, p<0.001
mg/day x 1 yr47 hypertension, symptoms, quality of life, ↓ NT-proBNP: baseline vs 1 yr:
70% NYHA class II, and global left ventricular Diuretics + ramipril: 488 ± 701 vs
20% had diabetes function 314 ± 422 pg/ml, p<0.001
(n=150) Diuretics + irbesartan: 568 ± 757 vs 443
± 603 pg/ml, p<0.001
Blood pressure: baseline vs 24 wks:
Diuretics: 145/80 vs 138/80 mm Hg, p<0.001
Diuretics + ramipril: 143/82 vs 137/76
mm Hg, p<0.001
Diuretics + irbesartan: 144/82 vs 136/76
mm Hg, p<0.001
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peak systolic strain, and cyclic variation of
integrated backscatter (i.e., had improved
ventricular systolic function). Of interest, this
effect was independent of blood pressure
reduction, and there were minimal effects on
ventricular diastolic function.
A pilot study randomly assigned 44 patients
with heart failure with PEF to receive eplerenone
started at 25 mg/day and titrated to 50 mg/day or
placebo.57 Diagnosis of heart failure with PEF
was defined as NYHA class IV symptoms on
previous hospital admission or symptoms
consistent with heart failure, BNP levels greater
than 100 pg/ml, LVEF greater than 40%, and
echocardiographic evidence of diastolic dysfunc-
tion. Nearly all patients were taking an ACE
inhibitor (64%) or ARB (34%) at baseline, and
most (68%) were also taking -blockers. Serum
markers of collagen turnover and inflammation
including procollagen types I and III amino-
terminal peptides, matrix metallo-proteinase type
2, interleukin-6 and -8, and tumor necrosis
factor-, were analyzed at baseline and at 6 and
12 months. Doppler echocardiographic assess-
ment of diastolic filling indexes and tissue
Doppler analyses, in addition to NYHA func-
tional class and quality-of-life score, were also
obtained. Eplerenone signifi-cantly attenuated
the increase in procollagen type III amino-
terminal peptides from baseline to 12 months
and produced a significant reduction in
deceleration time compared with placebo during
the study, but no other changes in diastolic
functional markers were seen. Of importance,
the benefit of eplerenone in this study was seen
despite the use of other drugs that directly or
indirectly affect RAAS activity.
Current data suggest that aldosterone
antagonism may be beneficial in decreasing
myocardial stiffness and improving myocardial
relaxation independent of blood pressure
reduction. Studies have shown that aldosterone
antagonists may also be able to improve
ventricular systolic function, decrease myocardial
wall thickness, and reduce collagen formation in
patients with heart failure with PEF. As noted
with ACE inhibitors and ARBs, aldosterone
antagonists may also be important agents in
hypertension management, a common cause of
heart failure with PEF. Other ongoing studies,
such as the Aldosterone Antagonist Therapy for
Adults with Heart Failure and Preserved Systolic
Function (TOPCAT) trial, may provide future
information on aldosterone antagonists (Table 4).
-Blockers
Increased heart rate causes an increase in
myocardial oxygen demand and decreases
coronary perfusion time, which may be
important in patients with heart failure with PEF
and coronary artery disease. Controlling heart
rate may be important in patients with heart
failure with PEF for other reasons, as incomplete
ventricular relaxation between beats may cause
an increase in diastolic pressure relative to
diastolic volume.68, 69 However, at least some
patients with heart failure with PEF have
chronotropic incompetence,38 and the optimal
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Study Treatment and
Duration of Follow-up Study Population Study Objective Significant Results
Diuretics (continued)
Chorthalidone vs mean age ~69 yrs, To compare treatments Death after first heart failure
lisinopril, > 30% women with regard to hospitalization: 29.2% PEF vs 41.9% REF,
chlorthalidone vs (n= 910) hospitalization for p<0.001
amlodipine, and PEF vs REF heart failure ↓ new-onset heart failure with PEF:
chlorthalidone vs Chlorthalidone vs lisinopril: HR 0.74,
doxazosin41 95% CI 0.56–0.97, p=0.032
Chlorthalidone vs amlodipine: HR 0.69,
95% CI 0.53–0.91, p=0.009
Chlorthalidone vs doxazosin: HR 0.53,
95% CI 0.38–0.73, p<0.001
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; NYHA = New York Heart Association; LVEF = left ventricular
ejection fraction; MI = myocardial infarction; E:A ratio = ratio between early velocity from ventricular filling to late velocity from atrial
contraction; SBP = systolic blood pressure; MLHFQ = Minnesota Living with Heart Failure Questionnaire; PEF = preserved ejection fraction;
PIINP = procollagen II N-terminal peptide; mPAP = mean pulmonary artery pressure; PWP = pulmonary wedge pressure; BNP = B-type (brain)
natriuretic peptide; EDV = end-diastolic velocity; Mva:Pva ratio = ratio of mitral A wave duration to pulmonary venous atrial systolic reversal
duration; REF = reduced ejection fraction; HR = hazard ratio; CI = confidence interval; NT-proBNP = N-terminal proBNP.
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Table 4. Ongoing Clinical Trials in Patients with Heart Failure with Preserved Ejection Fraction
ClinicalTrials.gov
Treatment Identifier Study Objective
Angiotensin II receptor blocker
Valsartan vs placebo 00241098 To evaluate the response of hypertension and early-stage heart failure
Valsartan vs placebo 00171106 To study the effects of valsartan on exercise tolerance
Aldosterone antagonists
Spironolactone vs 00094302 To evaluate the effectiveness of spironolactone in reducing all-cause
placebo (TOPCAT) mortality in patients with heart failure with PEF. The study began in
August 2006 and is expected to be completed in July 2013.
Eplerenone vs placebo 00293150 To determine the efficacy of eplerenone in patients with heart failure
(PREDICT) with PEF to reverse cardiac remodeling and improve diastolic function
Spironolactone vs placebo 00523757 To assess the change in markers of collagen turnover and correlate
(ARCTIC-D) this with specific measures of left ventricular mass by magnetic
resonance imaging, collagen markers, other biomarkers, clinical
outcomes, quality of life, and exercise testing
Eplerenone vs placebo 00108251 To determine whether eplerenone has a benefit on exercise ability in
patients with heart failure with PEF
Spironolactone 00206232 To observe spironolactone’s safety and effectiveness in women
Renin inhibitor
Aliskerin + spironolactone 00773084 To compare effects of two different combinations of heart failure
vs lisinopril + drugs on certain blood markers that cause or worsen heart failure
spironolactone (ARID-HF)
Statins
Statin vs no statin Not applicable Statins are thought to have a protective effect on left ventricular
remodeling and fibrosis. This study’s preliminary report showed
that receipt of statin therapy significantly improved survival rate
and remained beneficial after adjusting for differences in baseline
characteristics (relative risk 0.20, 95% confidence interval 0.06–0.62,
p=0.005).67
Atorvastatin vs placebo 00585611 To compare the change in carotid-femoral pulse wave velocity and
change in flow-mediated dilation between groups
Phosphodiesterase-5
inhibitor
Sildenafil vs placebo 00763867 To evaluate the effectiveness of sildenafil in reversing cardiac
(RELAX) hypertrophy and interstitial fibrosis, inhibiting catecholamine-
stimulated hypertrophy, decreasing pulmonary vascular resistance
and pressure, stimulating myocardial relaxation, and promoting
antiproliferative effects
Ranolazine
Ranolazine 00574756 To evaluate the effect of ranolazine on echocardiographic indexes
of diastolic dysfunction
Endothelian receptor
antagonists
Bosentan vs placebo 00820352 To evaluate the safety and efficacy of bosentan in patients with heart
failure with PEF and secondary pulmonary hypertension
Ambrisentan vs placebo 00840463 To evaluate the safety and efficacy of ambrisentan to treat pulmonary
hypertension associated with heart failure with PEF
Sitaxsentan vs placebo 00303498 To explore if sitaxsentan is effective in the treatment of heart failure
(phase II study) with PEF
Recombinant human BNP
Nesiritide 00309868 To study the acute hemodynamic and myocardial effects of nesiritide
in patients with heart failure with PEF
Xanthine oxidase inhibitor
Allopurinol 00477789 To assess whether a reduction of uric acid levels will favorably affect
diastolic function in patients with chronic heart failure
TOPCAT = Aldosterone Antagonist Therapy for Adults with Heart Failure and Preserved Systolic Function; PEF = preserved heart failure;
PREDICT = Eplerenone in Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure;
ARCTIC-D = Aldosterone Blockade in Heart Failure; ARID-HF = Aliskerin and Renin Inhibition in Diastolic Heart Failure; RELAX = Evaluating
the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People with Diastolic Heart Failure; BNP = B-type (brain)
natriuretic peptide.
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heart rate may not be the same for all patients.
In heart failure with REF, chronic stimulation of
the sympathetic nervous system promotes
ventricular remodeling that can be prevented
with the use of -blockers; whether similar
effects with -blockers will occur in heart failure
with PEF is unknown. Despite the lack of large
trials supporting the use of -blockers in patients
with heart failure, data from the Acute Decom-
pensated Heart Failure Registry (ADHERE),
which contains information on over 100,000
heart failure–related hospitalizations, showed
that more than 60% of 17,045 patients with LVEF
greater than 40% received -blockers.13
A 1997 study sought to prove a mortality
benefit for -blockade in patients with heart
failure with PEF who previously had experienced
a myocardial infarction.45 The study population
of 158 patients had NYHA class II or III symp-
toms, previous Q-wave myocardial infarction,
and an LVEF of 40% or greater after 2 months of
treatment with an ACE inhibitor and diuretics.
Patients were randomly assigned to receive
propranolol starting at 10 mg/day with dosage
titration to a target of 30 mg 3 times/day or
placebo, and followed for a mean of nearly 3
years. All patients were receiving a diuretic and
an ACE inhibitor, 33% were receiving digoxin,
and more than 60% had a history of hypertension.
One year after randomization, propranolol-
treated patients had a significant increase in
LVEF and reduction in left ventricular mass.
Multivariable Cox regression analysis modeling
showed significant benefits of propranolol
treatment at a mean follow-up of 32 months,
with an odds ratio of 0.65 (95% confidence
interval [CI] 0.44–0.96, p=0.03) and 0.63 (95%
CI 0.43–0.92, p=0.02) for total mortality and
total mortality plus nonfatal myocardial
infarction, respectively.
A more contemporary prospective trial
randomly assigned 26 patients to receive atenolol
or nebivolol and compared exercise hemodynamic
parameters and maximal exercise capacity.58
Entry criteria included NYHA class II or III
symptoms for at least 6 months, peak volume of
oxygen consumption of 25 ml/kg/minute,
evidence of normal systolic function (defined by
an LVEF ≥ 50% and end-diastolic diameter < 32
mm/m2), and diastolic dysfunction (defined by
E:A ratio < 1.0 and/or pulmonary capillary wedge
pressure > 12 mm Hg at rest and/or > 20 mm Hg
at peak exercise). Exclusion criteria were active
myocardial ischemia, valvular or congenital heart
disease, resting systolic blood pressure greater
than 200 mm Hg or diastolic blood pressure
greater than 100 mm Hg, atrial fibrillation, or
contraindications to -blockers. All patients
underwent cardiopulmonary exercise testing and
echocardiography with Doppler measurements at
baseline and after 6 months of treatment.
Furosemide was given to all but one patient, and
an ACE inhibitor or ARB was given to all but one
patient in each treatment arm. Of the 13 patients
in each treatment arm, 7 of those receiving
atenolol and 8 of those receiving nebivolol were
also receiving amlodipine. Atenolol and
nebivolol doses were titrated from 50 to 100
mg/day and from 2.5 to 5 mg/day, respectively.
Nebivolol, but not atenolol, significantly
increased the volume of oxygen consumption
from baseline, although there was no significant
difference in the magnitude of change between
groups. No significant change from baseline was
noted in end-diastolic diameter or LVEF in either
group. Both groups showed similar decreases in
left ventricular end-diastolic septal wall thickness.
Significantly less reduction in cardiac index, less
increase in systemic vascular resistance, greater
decrease in mean pulmonary artery pressure,
greater increase in the E:A ratio, and greater
decrease in pulmonary wedge pressure favored
nebivolol over atenolol, both at rest and during
peak exercise. Systemic vascular resistance
changes were only significant at rest and not
during peak exercise.
The Swedish Doppler Echocardiographic
(SWEDIC) study was a prospective, randomized,
double-blind, placebo-controlled trial that
compared the effects of carvedilol on diastolic
function in patients with diastolic heart failure
and preserved systolic function versus placebo.59
Included patients had a wall motion index of 1.2
or less (corresponding to LVEF > 45%) and
evidence of abnormal diastolic function. The
primary end point was improvement in a
diastolic dysfunction score measured by changes
in four echocardiographic diastolic variables. In
all patients, carvedilol dose was titrated to the
maximum tolerated (target of 25 or 50 mg
twice/day), with 82% of patients achieving the
target dose. Ninety-seven of 113 patients
completed the entire study with sufficient data.
There was no statistically significant difference in
the primary end point between groups, but there
was a significant increase in age-adjusted E:A
ratio in the carvedilol group. The authors noted
that when the data were analyzed by subgroups
based on resting heart rate, patients with heart
rates of 71 beats/minute or higher had a higher
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E:A ratio (i.e., improved early diastolic filling),
whereas those with heart rates lower than 71
beats/minute did not. One of the limitations of
this study was its small study size; a larger study
would need to be conducted before confirming
the benefits of carvedilol on ventricular diastolic
function.
Another small study compared carvedilol in 19
patients with conventional therapy in 21 patients
who had been referred to an outpatient heart
failure clinic in Japan.60 Patients had been
treated with conventional therapy—ACE
inhibitors, diuretics, and/or digitalis—for 3 or
more months. Carvedilol was started at 1.25
mg/day, with doubling every week until a dose of
more than 5 mg/day. Greater increases were
made by the attending cardiologists to a
maximum carvedilol dose of 20 mg/day (mean
dose of 10.6 mg/day), generally considered the
maximum dose for Japanese patients. Conven-
tional therapy was continued. All patients in
both groups were provided guidelines for lifestyle
modification. If patients came to the clinic with
a heart failure exacerbation, the carvedilol group
had their dosage of diuretic up-titrated, but no
changes could be made to other cardiovascular
drugs; patients in the conventional group could
also have their diuretic dosage increased but
could also have an ARB administered if they had
experienced no diuretic effect. Treatment failure
was defined as death from any cause, hospitali-
zation, use of inotropic agents to treat exacer-
bation, exercise intolerance with NYHA class IV
symptoms after treatment adjustment, or
carvedilol intolerance. After 12 months of
treatment, carvedilol was found to significantly
reduce BNP levels, improve NYHA functional
class symptoms, and increase exercise capacity.
Although this was a small trial, it can be hypothesis
generating for a larger trial.
A subanalysis of the Study of Effects of
Nebivolol Intervention on Outcomes and
Rehospitalization in Seniors with Heart Failure
(SENIORS) trial examined the effects of an LVEF
of 35% or less in 1359 patients (REF group) and
an LVEF greater than 35% in 752 patients (PEF
group) during treatment with nebivolol.61 The
primary outcome was time to first event of a
composite end point of all-cause mortality or
cardiovascular hospitalization. Eligible patients
were aged 70 years or older and had a clinical
history of heart failure, with either documented
hospital admission within 12 months with a
discharge diagnosis of chronic heart failure or an
LVEF less than 35% within the previous 6
months. Concomitant drugs in the PEF group
included a diuretic (83% of patients), ACE
inhibitor (82%), ARB (5.6%), aldosterone
antagonist (5.6%), cardiac glycoside (40.4%),
antiarrhythmic agent (17.7%), lipid-lowering
agent (13.3%), and calcium channel blocker
(18.9%). Aldosterone antagonists and ARBs were
used less frequently in the PEF group versus the
REF group: 5.6% versus 32.1%, and 5.6% versus
9.9%, respectively. The nebivolol dose was
titrated from 1.25 mg/day to a target dose of 10
mg/day over 16 weeks.
Both groups showed a significant reduction in
heart rate with nebivolol versus placebo. Overall,
nebivolol produced a significantly decreased left
ventricular end-diastolic volume, increased LVEF,
and increased echocardiographic fractional
shortening (a measure of systolic function)
within both groups combined, but within the
PEF population, only a significant increase in
LVEF was noted. The occurrence of primary
outcomes was not significantly different between
patients with heart failure with PEF (31.2%) and
those with heart failure with REF (34.2%). The
hazard ratio (HR) of -blockade versus placebo
between the subgroups was similar for the
primary outcome (HR 0.86, 95% CI 0.72–1.04 vs
HR 0.81, 95% CI 0.63–1.04, p=0.720). To ensure
primary and secondary outcome results were not
related to choice in LVEF cutoff, investigators
looked at the effects of nebivolol versus placebo
in 643 patients with LVEF of 40% or greater and
found results similar to those with LVEF of 35%
or greater. A limitation of this study is that it was
not powered to show an effect of nebivolol
between subgroups of LVEF, but these post hoc
analyses suggest potential benefit in patients with
heart failure with PEF. With nebivolol’s effect on
nitric oxide, there is a question of whether these
data can be extrapolated to other -blockers.
The HFSA recommends that blood pressure be
controlled to a target of lower than 130/80 mm
Hg, and treatment with a -blocker could be
considered in addition to other agents. The
HFSA also recommends -blockers in patients
with heart failure with PEF and atrial fibrillation,
or previous myocardial infarction.18 -Blockers
appear to decrease mortality in patients with
heart failure with PEF after previous Q-wave
myocardial infarction and may have a role in
increasing LVEF, improving hemodynamic
parameters, and increasing exercise capacity. In
addition, data from the large SENIORS trial
suggest similarity in clinical outcomes between
-blockers in heart failure with PEF and heart
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failure with REF.61 In addition to the use in
patients with atrial fibrillation or previous
myocardial infarction as recognized in the
guidelines, -blockers can be considered for
treatment of heart failure with PEF for patients
without contraindications. It is important to
note that some patients with heart failure with
PEF have chronotropic incompetence, which
may limit the use of -blockers in this
population.
Calcium Channel Blockers
The use of nondihydropyridine calcium
channel blockers in patients with hypertrophic
cardiomyopathy results in improved diastolic
filling. With this concept in mind, calcium
channel blockers could be beneficial in patients
with heart failure with PEF. Nondihydropyridine
agents are more selective for the myocardium
with less vasodilatory effects, whereas dihydro-
pyridine agents are highly vascular selective.
More specifically, calcium channel blockers bind
to L-type calcium channels blocking entry of
calcium and promoting relaxation. Most data
about heart failure with PEF and calcium channel
blockers are with nondihydropyridine agents.
A placebo-controlled, crossover trial assessed
the effects of verapamil in patients with heart
failure with PEF over 5 weeks.62 Twenty men
with heart failure symptoms for more than 3
months, an LVEF greater than 45%, and
abnormal peak diastolic filling rate were assigned
to receive verapamil or placebo. Patients were
graded through a scoring system with points
assigned for increasing grades of dyspnea,
pulmonary congestion, jugular venous
distension, third heart sound, and peripheral
edema, with the highest score of 13 signifying the
most severe heart failure. Patients taking digoxin
discontinued therapy 7 days before study start,
but diuretics could be continued. When
beginning verapamil therapy, patients were given
verapamil 80 mg 3 times/day with up-titration to
120 mg 3 times/day or down-titration to 80 mg
twice/day based on tolerance (mean daily dose =
256 mg). Statistically significant improvement in
heart failure score was noted in the verapamil
group compared with the placebo group.
Although only 12 (60%) of 20 patients were
capable of exercise, verapamil significantly
improved exercise capacity by 33% compared
with baseline values. In addition, peak filling
rate increased significantly by 30% with
verapamil compared with baseline (p<0.05).
Mean LVEF and systolic blood pressure were
unchanged from baseline. The authors suggested
that potential mechanisms of verapamil could be
alteration of left ventricular filling, reversal of
subclinical ischemia, and alteration of cellular
calcium metabolism. The study is limited by its
small sample size and the entirely male study
population, which is noteworthy due to the
increased prevalence of heart failure with PEF in
women.
Fifteen elderly patients with normal LVEF were
randomly assigned to receive verapamil or
placebo in a 3-month, placebo-controlled,
crossover trial.63 Heart failure scores were used
for group comparisons and reflected clinical
assessment parameters (dyspnea, pulmonary
congestion, neck vein distension, peripheral
edema, pulmonary edema on independently read
chest radiographs, a Bruce modified exercise test,
and echocardiograms), with higher scores
representing a worsened clinical picture. Patients
had significantly improved heart failure scores
and exercise time during verapamil treatment.
No significant changes were noted in LVEF, left
ventricular mass, heart rate, or cardiac output,
and effects on diastolic function were mixed with
reduced isovolumic relaxation time, increased
peak velocity of mitral A wave to peak flow
velocity and duration of the flow reversal during
atrial systole (Mva:Pva) ratio, but no change in
E:A ratio and E-wave deceleration time.
Data on dihydropyridine calcium channel
blockers in patients with heart failure with PEF
are limited. In the ALLHAT trial, which was a
large comparison of several pharmacologic
hypertension treatment strategies, chlorthalidone
decreased the occurrence of new-onset heart
failure with PEF significantly more than
amlodipine.41 The Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT) compared blood
pressure control in patients with hypertension
randomly assigned to an amlodipine-perindopril
or an atenolol-thiazide regimen. Of interest, a
recent subanalysis of ASCOT suggested that
patients receiving the amlodipine-based regimen
had better diastolic function.70 Whether this
effect was due more in part to amlodipine or
perindopril cannot be determined from this
analysis.
The 2008 European Heart Failure guidelines
suggest that calcium channel blockers may be
useful to improve symptoms and exercise
capacity.65 The HFSA recommends that blood
pressure be controlled to a target of less than
130/80 mm Hg, and treatment with a calcium-
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channel blocker in addition to other agents could
be considered. Published trials with calcium
channel blockers are mostly limited to non-
dihydropyridine agents, more specifically
verapamil. These pilot studies suggest benefit in
reducing heart failure scores, increasing exercise
capacity, and altering left ventricular diastolic
parameters, but their results need to be confirmed
in larger populations. Again, the possibility of
chronotropic incompetence may limit the use of
nondihydropyridine calcium channel blockers in
some patients.
Digoxin
It has been suggested that digoxin may
produce an increase in systolic energy demands,
add to a relative calcium overload in diastole, and
contribute to diastolic dysfunction. The exact
mechanism of how digoxin may benefit patients
with heart failure with PEF is not clearly
understood.68 Nonetheless, as an ancillary part
of the Digitalis Intervention Group (DIG) trial,
the effect of digoxin (492 patients) versus
placebo (496 patients) was evaluated in patients
with an LVEF greater than 45% by assessing the
occurrence of death or hospitalization due to
worsening heart failure as a combined primary
outcome.64 In the main study, all patients (REF
and PEF) randomly assigned to the digoxin
group received one of four algorithm-derived
doses.71 Most patients were receiving diuretics
and ACE inhibitors. Patients with an LVEF of
45% or less (6800 patients) had a significantly
reduced rate of hospitalizations for heart failure
compared with the placebo group (26.8% vs
34.7%, p<0.001). In the main study, no
significant difference in event rates was noted in
patients with heart failure with PEF.
However, a more recent analysis was conducted
with 916 pairs of patients (1832 total patients)
with PEF and REF, with baseline characteristics
balanced by propensity matching.64 With use of
the same primary outcome of heart failure
hospitalization or mortality as in the original DIG
trial, a statistically significant benefit was seen
with digoxin in both heart failure with REF and
heart failure with PEF at the end of 2 years.
Digoxin also significantly decreased heart
failure–related hospitalization alone in both
groups. At the end of the analysis period
(median 3.2 yrs), no significant difference was
seen between digoxin or placebo in either the
REF group (HR 0.85, 95% CI 0.67–1.08,
p=0.188) or PEF group (HR 0.79, 95% CI
0.60–1.03, p=0.085), possibly due to the
crossover design and higher digoxin doses.
There was also no significant difference seen in
heart failure–related hospitalizations alone
between the REF group (HR 0.80, 95% CI
0.62–1.03, p=0.079) and PEF groups (HR 0.77,
95% CI 0.57–1.03, p=0.074). Of interest, digoxin
(an inotropic agent) was not found to be
detrimental in patients with heart failure with
PEF and may prove to be beneficial.
Although the 2010 HFSA guidelines do not
address the use of digoxin in the management of
heart failure with PEF, the data above suggest
digoxin can be considered for use to decrease
hospitalizations in patients with heart failure
with PEF. Any additional role, beyond reduction
of hospitalizations, will need to be investigated in
future studies.
Diuretics
In patients with heart failure with PEF, the
stiffened ventricles rely on higher than normal
filling pressures to provide adequate cardiac
output,21 making these patients sensitive to the
preload reduction induced by diuresis. However,
diuretics are clinically useful to reduce pulmonary
congestion and peripheral edema, creating a
narrow therapeutic window for the use of
diuretics in patients with heart failure with PEF.
In one study, 150 patients were randomly
assigned to receive diuretics alone, diuretics plus
ramipril, or diuretics plus irbesartan.47 The
hypothesis was that the addition of irbesartan or
ramipril to diuretics would be superior to
diuretics alone with respect to quality of life and
ventricular function. Study inclusion criteria
were as follows: age older than 18 years, clinical
history of heart failure within the past 2 months
with pulmonary congestion, NYHA classes II–IV,
LVEF greater than 45%, and therapy with a stable
dosage of diuretics more than 14 days before
recruitment. The primary end points were
symptoms (exercise capacity as measured by the
6-minute walk test), quality of life (the Minnesota
Heart Failure Symptom Questionnaire), and
ventricular function (echocardiographic
measurement), assessed at baseline and at 12, 24,
and 52 weeks. The initial dose of irbesartan was
18.75 mg/day with titration to 75 mg/day.
Ramipril was initially started at 2.5 mg/day and
titrated to 10 mg/day. At baseline, 68–80% of
patients were receiving furosemide, 6–10%
hydrochlorothiazide, ~5% indapamide, and
1–12% hydrochlorothiazide-triamterene.
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Echocardiographic results did not show
improvement in left ventricular dimensions or
LVEF with ramipril and irbesartan added to
diuretic therapy. The 6-minute walk test
improved slightly, but without clinical or
statistical significance. Blood pressure was
significantly reduced from baseline in all groups,
but was not significantly different between
groups. The NT-proBNP levels were significantly
improved from baseline with irbesartan and
ramipril, but again was not significantly different
between treatment groups. Quality of life was
significantly improved across all study groups,
with no additional benefit seen with the addition
of ramipril or irbesartan. If targeting sympto-
matic relief and increased quality of life in elderly
patients, diuretic therapy alone may provide
similar improvement to additional ACE inhibitor
and ARB therapy.
Of the 42,418 ALLHAT study participants,
1367 had heart failure events (validated by the
Heart Failure Evaluation Study); 910 of those
patients had an LVEF assessment; 44.4% had
heart failure with PEF (LVEF ≥ 50%), and 56%
had heart failure with REF (LVEF < 50%).41
Patients aged 55 years or older with hypertension
and one additional risk factor for coronary heart
disease were included. Patients with a history of
symptomatic heart failure, history of hospital-
ization for heart failure, or known LVEF less than
35% were excluded. Patients were randomly
assigned to receive chlorthalidone, amlodipine,
lisinopril, or doxazosin. Chlorthalidone treatment
was compared with each of the other treatment
arms. Chlorthalidone reduced the risk of new-
onset heart failure with PEF compared with
amlodipine (HR 0.69, 95% CI 0.53–0.91,
p=0.009), lisinopril (HR 0.74, 95% CI 0.56–0.97,
p=0.032), and doxazosin (HR 0.53, 95% CI
0.38–0.73, p<0.001). Critics suggest that
peripheral edema may have been misclassified as
heart failure with PEF, although all incident cases
were diagnosed at the time of hospitalization for
heart failure, and events were independently
adjudicated.
The 2008 European guidelines recommend
that diuretics be used to control sodium and
water retention, relieve shortness of breath, and
reduce edema.65 The HFSA recommends
diuretics in all volume-overloaded patients with
heart failure with PEF, with treatment beginning
with a thiazide diuretic and transitioning to a
loop diuretic if poor response to the thiazide
occurs. The HFSA also recommends that blood
pressure be controlled to a target less than 130/80
mm Hg, and treatment with a diuretic should be
considered.18 In addition to reducing pulmonary
congestion and peripheral edema, diuretics may
prevent the development of new-onset heart
failure, improve quality of life, and decrease BNP
levels in patients with heart failure with PEF.
Clinical Implications
How should clinicians manage a patient who
presents with symptoms of heart failure and
normal LVEF? Although symptomatic manifes-
tation of heart failure with PEF may be very
similar to that of heart failure with REF, treatment
for both types of heart failure may not be
identical. A vast amount of literature and detailed
guidelines exist for the short- and long-term
management of patients with heart failure with
REF, but the same is not true for those with heart
failure with PEF. Clinicians should focus on
controlling and treating underlying causes of the
disease state and known risk factors, in
particular, hypertension.
In patients with hypertension who have
multiple risk factors for development of heart
failure with PEF, thiazide diuretics may prevent
the development of new-onset heart failure.41 If
blood pressure cannot be controlled with diuretics
alone, the appropriate agents to add have not
been fully defined. Blockade of the RAAS system
through the use of ACE inhibitors or ARBs may
provide symptomatic improvement, improve
quality of life, increase exercise duration, and
decrease left ventricular mass, but the effects of
these agents on other clinical outcomes including
mortality are not yet clear. It is reasonable to use
an ACE inhibitor or ARB for blood pressure
reduction in the setting of atherosclerotic heart
disease or diabetes, but there is a lack of
information to support use of these agents in a
patient with controlled hyper-tension without
another indication. Aldosterone antagonists may
reduce inflammation and fibrosis, while also
providing hypertensive control and improve-
ments in diastolic function. Nondihydropyridine
calcium channel blockers and -blockers
improved exercise capacity in small studies but
had mixed effects on ventricular diastolic func-
tion and may exacerbate symptoms in patients
with chronotropic incompetence. -Blockers do
appear to benefit patients with heart failure with
PEF and a previous myocardial infarction and
should be considered for patients without contra-
indications. The use of digoxin in patients with
heart failure with PEF without atrial fibrillation
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remains controversial, but the drug can be used
to reduce the frequency of hospitalization, as it
does in patients with heart failure with REF.
Diuretics reduce and prevent fluid accumulation
and improve quality of life. In addition to
pharmacologic management, nonpharmacologic
treatments including the following therapeutic
lifestyle modifications should be considered for
all patients18:
• Low-fat diet in patients with obesity,
diabetes, hyperlipidemia, or vascular disease
• Low-sodium diet (2–3 g for mild heart failure
and < 2 g for moderate-to-severe heart
failure)
• Regular exercise
• Weight loss
• Restriction of fluid intake in severely affected
patients
• Daily weight monitoring
• Smoking cessation
• Limited alcohol consumption
• Limited caffeine intake
Conclusion
Overall, the results of pharmacologic treatment
trials in patients with heart failure with PEF have
been disappointing. In large part, this reflects
incomplete understanding of what is now
recognized as a physiologically heterogenous
disease. Future trials must take this hetero-
geneity into account when defining inclusion
criteria. Efforts to standardize diagnostic
guidelines should aid in more careful heart
failure with PEF phenotyping. In addition,
because of a lower cardiac mortality rate in
patients with heart failure with PEF than those
with heart failure with REF, clinical trials should
focus more on quality-of-life and hospitalization
end points. Although specific treatment for heart
failure with PEF still remains to be clearly
defined, treatment regimens within and beyond
the typical therapeutic classes are being
investigated. Until the results of these studies are
available, treatment options for this major public
health threat will be based on the limited data
that currently exist.
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